Adding Lynparza to standard treatment for early-stage HER2-negative breast cancer with a high risk of recurrence in people with a BRCA1 or BRCA2 mutation improved disease-free survival.
The latest results from the PALOMA-3 trial show that combining Ibrance and Faslodex continues to offer better overall survival than Faslodex alone.
Adding Tukysa to the standard of care of Herceptin and Xeloda continued to improve both progression-free and overall survival in people diagnosed with either metastatic or unresectable locally advanced HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.
Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.
Nearly all the people in a clinical trial who were receiving systemic intravenous cancer treatment had an adequate immune response to the Pfizer-BioNTech COVID-19 vaccine.
A study suggests that a drug that is a biosimilar to Herceptin, called MYL-1401O, is as effective as Herceptin and has similar side effects.
FDA approves Piqray in combination with Faslodex to treat metastatic and advanced-stage, hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation that has grown after hormonal therapy treatment in postmenopausal women and men.
Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.
Updated results show adding Perjeta to Herceptin and chemotherapy after surgery for early-stage HER2-positive breast cancer continues to reduce the risk of recurrence and to slightly improve survival.
The FDA has approved Ibrance to treat men diagnosed with advanced-stage hormone-receptor-positive, HER2-negative breast cancer.
The latest results from the MONALEESA-3 study show that combining Kisqali plus Faslodex continues to offer better overall survival than Faslodex alone.
For people with HER2-positive breast cancer that has spread to the brain, adding Tukysa to standard treatment improved survival and reduced the risk that the brain lesions would grow.
Research on cells suggests that HER2-positive breast cancers resistant to Herceptin may respond to Tykerb.
The FDA has approved Talzenna (chemical name: talazoparib) to treat locally advanced or metastatic HER2-negative breast cancer in women with an inherited BRCA1 or BRCA2 mutation.
While 9 weeks of Herceptin was associated with fewer heart problems compared to 1 year of Herceptin, the difference in disease-free survival was small and the researchers said 1 year of Herceptin should remain the standard of care.
A study suggests that an injectable form of Herceptin works just as well as and is as safe as the standard IV form of Herceptin to treat HER2-positive, early-stage breast cancer before surgery.
On March 11, 2019, the FDA approved Trazimera (chemical name: trastuzumab-qyyp), a biosimilar for Herceptin, to treat people diagnosed with HER2-positive breast cancer.
Herceptin plus hormonal therapy for advanced breast cancer is approved in Europe.
A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.
A study found that more than 25% of people with an abnormal BRCA1 or BRCA2 gene being treated for advanced-stage breast, ovarian, pancreatic, or prostate cancer got some benefit from olaparib, an experimental targeted therapy medicine.
A small, early study suggests that a combination of Herceptin and Taxol seemed to reduce the risk of recurrence of small HER2-positive breast cancers that hadn't spread to the lymph nodes.
Adding experimental tucatinib to the standard of care of Herceptin and Xeloda improved both progression-free survival and overall survival in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.
Some metastatic, HER2-positive breast cancers will respond to Herceptin for several years, suggesting that long-term remission is possible.
An FDA expert panel recommended that Avastin not be used to treat advanced breast cancer. But doctors may still recommend the medicine depending on a woman's unique situation.